How much revenue does Keymed Biosciences make?

Keymed Biosciences reported 716.31 million CNY in revenue for fiscal year 2025, up 67.3% from 428.12 million CNY in fiscal year 2024.

Where does Keymed Biosciences make most of its revenue?

Overseas: 91% of revenue by region in fiscal year 2024, followed by Mainland China (9%).

What companies are similar to Keymed Biosciences?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK), Akeso, Inc. (9926.HK), Shanghai Henlius Biotech, Inc. (2696.HK), HBM Holdings Limited (2142.HK).

Keymed Biosciences Inc. (2162.HK) Stock

About Keymed Biosciences Inc.

Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom. The company develops Kangyueda for the treatment of moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis; ...

At a glance

Keymed Biosciences reported revenue of 716.31 million CNY for fiscal year 2025, up 67.3% from fiscal year 2024, and net income of -522.64 million CNY. Overseas was its largest region in fiscal year 2024, with 91% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.